Stealth BioTherapeutics Granted Fast Track Designation for the Treatment of Barth Syndrome
Stealth BioTherapeutics (Stealth) announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for its lead candidate, elamipretide, for the treatment…
Read More...
Read More...
